Rx Drug Mart (RXDM) has received approval from the Competition Bureau to purchase 27 Rexall pharmacies across Canada. The sale was imposed as a condition under a consent agreement reached between the Bureau and McKesson, who proposed to acquire Rexall last year. To address the Bureau's concerns regarding the anti-competitive effect that the proposed acquisition may have in the pharmacy products and services market, McKesson had agreed to sell 27 Rexall retail pharmacies in 26 communities to its competitor, RXDM. McKesson's other proposed acquisition of Uniprix will also be reviewed by the Bureau.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.